This project will study the incorporation of individual patient related geometric uncertainties in the calculation,? compilation and treatment of optimized radiotherapy dose distributions. Even advanced treatment planning? techniques nearly always rely on population-based rules to ensure that the majority of patients receive? adequate dose in the face of positioning errors and organ motion. This """"""""one size fits all"""""""" approach potentially? penalizes patients who exhibit exceptionally large variation in position or motion, requiring more intensive? measures to ensure adequate target volume coverage. However, it also penalizes a substantial proportion of? patients with less uncertainty in their target position, who through the use of smaller margins would be at? lesser risk for treatment related toxicity or eligible for higher tumor dose. We believe that a new combined? approach involving a) dose computation strategies that already include the effects of geometric uncertainties,? b) rigorous in-room methodologies for rapidly assessing target and patient configuration and c) accounting? for delivered dose and its influence on subsequent treatment delivery optimization will yield improvements? in efficient and accurate dose delivery, optimally tailored for each patient. Thus, the project's specific aims are? to 1) implement general clinical frameworks for inclusion of patient related setup uncertainties and organ? motion into the computation of dose distributions, 2) assess improvements in accuracy achieved through inroom,? on-treatment measurement and action, 3) investigate human anatomic changes over short and long? time periods and how to accumulate dose to date using this information, and 4) determine the best ways to? react to differences between what is seen at treatment and what had been planned. In addition to better? tailoring overall treatments, these investigations will help determine how much complexity (in modeling,? measurement and intervention) is actually beneficial for a given patient, thus helping to establish the most? efficient use of advanced in-room imaging resources within the radiotherapy community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059827-13
Application #
7658877
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
13
Fiscal Year
2008
Total Cost
$383,185
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Ohri, Nitin; Tomé, Wolfgang A; Méndez Romero, Alejandra et al. (2018) Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys :
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Wang, Shulian; Campbell, Jeff; Stenmark, Matthew H et al. (2018) A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiother Oncol 126:506-510
Sapir, Eli; Tao, Yebin; Schipper, Matthew J et al. (2018) Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:122-130
Hawkins, Peter G; Boonstra, Philip S; Hobson, Stephen T et al. (2018) Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Transl Oncol 11:102-108
Sun, Yilun; Hawkins, Peter G; Bi, Nan et al. (2018) Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 100:107-114
Kong, Feng-Ming Spring; Li, Ling; Wang, Weili et al. (2018) Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol :
Shilkrut, Mark; Sapir, Eli; Hanasoge, Sheela et al. (2018) Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 41:326-331
Jackson, William C; Tao, Yebin; Mendiratta-Lala, Mishal et al. (2018) Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys 100:950-958
Miften, Moyed; Vinogradskiy, Yevgeniy; Moiseenko, Vitali et al. (2018) Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 289 publications